Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Relay Therapeutics (RLAY) will announce its fourth quarter and full-year 2025 financial results and corporate highlights on February 26, 2026, after market close. The company, which specializes in precision medicine for cancer and genetic diseases, will provide an update on its lead clinical asset, zovegalisib, a PI3Kα inhibitor in a Phase 3 trial for metastatic breast cancer, and other pipeline developments. Analysts have issued "Buy" ratings and price targets, while recent insider trading shows sales, and institutional investors have made significant portfolio adjustments.
Relay Therapeutics to Announce Fourth Quarter and Full Year
Relay Therapeutics, Inc. (Nasdaq: RLAY) will release its fourth quarter and full year 2025 financial results and corporate highlights after U.S. markets close on Thursday, February 26, 2026. The company is a clinical-stage, small molecule precision medicine company focused on developing therapies for cancer and genetic diseases. Its lead clinical asset, zovegalisib, is currently in a Phase 3 trial for metastatic breast cancer and is also being investigated for PI3Kα-driven vascular anomalies.
FDA Breakthrough Status For Zovegalisib Combo Might Change The Case For Investing In Relay Therapeutics (RLAY)
Relay Therapeutics (RLAY) received FDA Breakthrough Therapy designation for its drug zovegalisib in combination with fulvestrant for advanced breast cancer. This status could accelerate regulatory review and potentially enhance the investment case for Relay Therapeutics, although the company remains loss-making and reliant on external capital. The article highlights that while this is a significant milestone, investors should be mindful of the company's dependence on this single asset's success and consider various perspectives on its valuation.
Relay Therapeutics, Inc. (RLAY) Stock Analysis: 71% Upside Potential as Analysts Show Strong Buy Confidence
Relay Therapeutics, Inc. (RLAY) is a clinical-stage biotechnology company with a strong buy consensus from analysts, projecting a 71.29% upside potential. Despite not yet being profitable, typical for its stage, the company is advancing a robust pipeline of precision medicines for oncology and genetic diseases. Technical indicators suggest a bullish outlook, and strategic collaborations further enhance its position in the biotech sector.
Relay Therapeutics stock hits 52-week high at $9.16 By Investing.com
Relay Therapeutics (RLAY) stock hit a 52-week high of $9.16, demonstrating significant momentum with a 111.37% return over the past year. The biotech company's market capitalization stands at $1.52 billion, driven by its focus on precision medicines and recent FDA Breakthrough Therapy designation for its cancer treatment, zovegalisib. Analysts are optimistic, with price targets ranging from $12 to $19, despite expected unprofitability this year.
Relay Therapeutics (NASDAQ:RLAY) Sets New 12-Month High - Time to Buy?
Relay Therapeutics (NASDAQ:RLAY) recently hit a new 52-week high of $9.19, though it closed down about 4% at $8.63. Analysts have provided mixed ratings, with some upgrading the stock to "overweight" or "outperform" with price targets up to $14, contributing to a "Moderate Buy" consensus and an average price target of $16.57, despite the company remaining unprofitable and recent insider share sales.
Why Relay Therapeutics (RLAY) Is Up 9.4% After FDA Breakthrough Tag For Breast Cancer Combo
Relay Therapeutics (RLAY) saw its stock rise by 9.4% after the FDA granted Breakthrough Therapy designation for its breast cancer drug combination RLY-2608 plus fulvestrant. This designation, based on data from the ReDiscover trial, is expected to accelerate the development and regulatory pathway for the treatment of PIK3CA-mutant HR+/HER2- breast cancer. The news highlights the potential of Relay's precision oncology platform, though the company still faces challenges with unprofitability and trial risks despite its recent stock performance.
Relay Therapeutics stock hits 52-week high at $9.16
Relay Therapeutics (RLAY) has reached a new 52-week high of $9.16, with a market capitalization of $1.52 billion, driven by its focus on precision medicines and strong investor confidence. The company has shown a 111.37% return over the past year and a 177.02% gain in six months. Recent positive developments include the FDA granting Breakthrough Therapy designation for its cancer treatment zovegalisib and an upgrade from Oppenheimer to "Outperform" with a $14 price target.
Assessing Relay Therapeutics (RLAY) Valuation After Recent Share Price Momentum And Price To Book Discount
Relay Therapeutics (RLAY) has seen significant share price momentum recently, with a 9.45% gain in one day and a 44.57% gain over 90 days, bringing its 1-year total shareholder return to over 111%. Despite this, the company's valuation, evidenced by a Price to Book (P/B) ratio of 2.5x, is in line with the broader US biotech industry and significantly below its peers. This suggests the market is not assigning a premium to Relay Therapeutics, which is currently loss-making and relies on early-stage clinical assets, indicating a cautious outlook despite recent price surges.
Assessing Relay Therapeutics (RLAY) Valuation After FDA Breakthrough Therapy Designation For Zovegalisib
Relay Therapeutics (RLAY) received FDA Breakthrough Therapy designation for its breast cancer candidate zovegalisib, leading to increased investor interest and a sharp rise in share price. Despite recent gains and trading at a 37% discount to analyst targets, the company's P/B ratio of 2.5x matches the biotech industry average but is well below its closer peer group, suggesting a nuanced valuation. The article also highlights the company's net losses and reliance on successful trial outcomes as potential pressure points.
Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run
Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold 21,581 shares for approximately $166,700 to cover income tax withholding obligations from vested restricted stock units. This significant sale, representing 4.89% of his direct holdings, comes after the company's stock has seen a nearly 70% increase and received a Breakthrough Therapy designation from the FDA for its drug zovegalisib in advanced breast cancer. Despite the insider sale, which was involuntary, analysts maintain a moderate buy rating with an average price target of $16.57.
What Relay Therapeutics (RLAY)'s Zovegalisib Data and Insider Sales Mean For Shareholders
Analysts have upgraded Relay Therapeutics (RLAY) following new clinical data showing consistent efficacy for its investigational breast cancer drug zovegalisib, highlighting potential competitive advantages. Despite some insider share sales primarily for tax obligations, the positive clinical data reinforces the company's investment narrative, though questions remain about funding and potential overvaluation. Shareholders should consider both the promising pipeline developments and the company's financial sustainability.
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Relay Therapeutics, Inc. announced its management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026, at 10:30 a.m. ET. The event will be webcast live on the company's website. Relay Therapeutics is a clinical-stage precision medicine company focused on developing therapies for cancer and genetic diseases, with its lead asset zovegalisib currently in a Phase 3 trial for metastatic breast cancer.
Relay Therapeutics’ zovegalisib secures FDA BTD for advanced breast cancer
Relay Therapeutics has received FDA Breakthrough Therapy Designation (BTD) for zovegalisib (RLY-2608) in combination with fulvestrant for HR+/HER2- advanced breast cancer. This designation is for patients with PIK3CA-mutant, hormone receptor positive breast cancer who have experienced recurrence or progression after CDK4/6 inhibitors. The BTD aims to accelerate the development and review of this therapy, supported by positive data from the Phase I/II ReDiscover trial.
Relay Therapeutics stock rises after FDA grants Breakthrough Therapy status
Relay Therapeutics Inc. (NASDAQ:RLAY) saw its stock rise after the FDA granted Breakthrough Therapy designation to its cancer treatment, zovegalisib, combined with fulvestrant. This designation aims to accelerate the development and review of the drug for adults with specific types of breast cancer, particularly those who have recurred or progressed after prior treatments. The decision is backed by clinical data from the Phase 1/2 ReDiscover trial, with further data to be presented in March.
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
Relay Therapeutics announced that its drug, zovegalisib, has received Breakthrough Therapy designation from the U.S. FDA for treating PIK3CA-mutant, HR+/HER2- advanced breast cancer. This designation, supported by robust clinical data from the ReDiscover trial, aims to accelerate the development and review process for this potential new therapy. The drug targets a significant patient population for whom current therapeutic options are limited after CDK4/6 inhibitor treatment.
Relay Thera’s zovegalisib wins ‘Breakthrough’ status from FDA
Relay Therapeutics has received Breakthrough Therapy designation (BTD) from the FDA for its drug zovegalisib (RLY-2608) in combination with fulvestrant. This designation is for the treatment of adults with PIK3CA mutant, HR+/HER2- locally advanced or metastatic breast cancer that has progressed after CDK4/6 inhibitor treatment. Approximately 40% of patients with this type of breast cancer harbor PIK3CA mutations and have limited therapeutic options after CDK4/6 inhibitors, making this a significant recognition of zovegalisib's potential to improve outcomes.
Relay Therapeutics stock rises after FDA grants Breakthrough Therapy status
Relay Therapeutics Inc. (NASDAQ:RLAY) saw its stock rise after the FDA granted Breakthrough Therapy designation for its cancer treatment zovegalisib when combined with fulvestrant. This designation is for treating adults with PIK3CA mutant, HR+/HER2- locally advanced or metastatic breast cancer who have progressed after CDK4/6 inhibitor treatment. The Breakthrough Therapy status aims to accelerate the development and review of promising drugs for serious conditions.
Relay Therapeutics Announces Breakthrough Therapy Designation for Zovegalisib
Relay Therapeutics has received FDA Breakthrough Therapy designation for its drug zovegalisib, intended for advanced breast cancer treatment. This designation aims to expedite development for PIK3CA mutant HR+/HER2- breast cancer patients who have progressed after CDK4/6 inhibitor treatment. Supported by promising ReDiscover trial data, a Phase 3 trial update is anticipated at the ESMO Congress on March 16, 2026.
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
Relay Therapeutics announced that the U.S. FDA has granted Breakthrough Therapy designation to zovegalisib in combination with fulvestrant for PIK3CA-mutant, HR+/HER2- advanced breast cancer. This designation acknowledges the potential for substantial improvement over existing treatments, supported by robust clinical data from the ReDiscover trial. The company anticipates presenting further data at the ESMO Targeted Anticancer Therapies Congress, highlighting zovegalisib's role as a first-known allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor.
FDA fast-tracks Relay drug for hard-to-treat advanced breast cancer
Relay Therapeutics announced that the FDA has granted Breakthrough Therapy designation to its drug zovegalisib, in combination with fulvestrant, for treating PIK3CA-mutant, HR+/HER2- advanced breast cancer. This designation is supported by Phase 1/2 ReDiscover trial data and aims to accelerate the development and review process for this potential therapy. The drug targets a significant patient population with limited therapeutic options after progression on CDK4/6 inhibitors.
Relay Therapeutics announces Zovegalisib granted therapy designation by FDA for PIK3CA-mutant
Relay Therapeutics announced that its drug Zovegalisib received Breakthrough Therapy Designation from the FDA for treating PIK3CA-mutant cancers. This designation was granted specifically for Zovegalisib when used in combination with fulvestrant, for metastatic breast cancer patients. This recognition indicates the drug's potential for significant improvement over available therapies.
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
Relay Therapeutics announced that the U.S. FDA has granted Breakthrough Therapy Designation (BTD) to zogevalisib in combination with fulvestrant for advanced breast cancer patients with specific mutations. This designation, supported by clinical data from the ReDiscover trial, recognizes the potential of zogevalisib to significantly improve outcomes for this patient population. The BTD aims to accelerate the development and review process for this promising therapy.
Oppenheimer Notes Relay Therapeutics, Inc. (RLAY) Pipeline Strength in Mutant-Selective Inhibitors
Oppenheimer has upgraded Relay Therapeutics (RLAY) to Outperform with a $14 price target, citing the company's strong pipeline in mutant-selective inhibitors. The firm believes the upcoming VIKTORIA-1 trial results for Celcuity’s gedatolisib could set a favorable competitive benchmark for RLAY’s zovegalisib. Relay Therapeutics' zovegalisib has already shown promising interim clinical data with a median progression-free survival of 11.4 months in breast cancer patients.
Relay Therapeutics (NASDAQ:RLAY) Shares Up 7.2% - Here's Why
Relay Therapeutics (NASDAQ:RLAY) saw its shares increase by 7.2%, trading around $8.22 with about 1.01 million shares exchanged. This rise follows recent analyst upgrades from Wells Fargo and Oppenheimer, though the trading volume was down 53% from its average. Notably, company insiders, including CEO Sanjiv Patel and CFO Thomas Catinazzo, have sold stock in recent months.
Oppenheimer Notes Relay Therapeutics, Inc. (RLAY) Pipeline Strength in Mutant-Selective Inhibitors
Oppenheimer upgraded Relay Therapeutics (RLAY) from Perform to Outperform, setting a $14 price target due to the potential of its mutant-selective inhibitor, zovegalisib. The firm anticipates the upcoming VIKTORIA-1 trial results for Celcuity's gedatolisib to underperform, creating an opportunity for RLAY's zovegalisib to demonstrate competitive superiority, especially given its promising interim clinical data showing an 11.4 months median progression-free survival in breast cancer patients. Relay Therapeutics utilizes its Dynamo platform to target intractable protein targets for small-molecule therapies in oncology and genetic diseases.
What Relay Therapeutics (RLAY)'s Zovegalisib Data and Insider Sales Mean For Shareholders
Analysts have upgraded Relay Therapeutics (RLAY) following new clinical data showing consistent efficacy for its investigational breast cancer drug, zovegalisib. While insider stock sales by executives were primarily for tax obligations, the focus remains on the drug's potential and the company's ability to fund its ongoing clinical work. The article suggests that despite positive data, the company's valuation needs careful consideration due to potential overvaluation and the significant financial resources required for its pipeline development.
Relay Therapeutics (RLAY) Valuation Check After Analyst Upgrades And Zovegalisib Breast Cancer Data
Relay Therapeutics (RLAY) has seen renewed investor interest following analyst upgrades and positive interim data for its breast cancer drug zovegalisib. Despite a recent share price decline over 30 days, its one-year total shareholder return is up 69.82%. The company's price-to-book ratio currently suggests it is undervalued compared to peers, but it remains a clinical-stage company with ongoing losses and no guaranteed pipeline success.
Relay Therapeutics (NASDAQ:RLAY) Insider Sells 18,895 Shares
Relay Therapeutics insider Donald Bergstrom sold 18,895 shares of the company's stock for a total of $143,979.90, reducing his position by 4.28%. The move comes as RLAY trades near $7.71, with analysts projecting a mixed but generally positive outlook, holding a "Moderate Buy" consensus rating and a $16.57 average price target. The company, a clinical-stage biotechnology firm, continues to attract institutional investor interest despite missing recent quarterly EPS estimates.
Relay Therapeutics (NASDAQ:RLAY) Insider Sells $11,441.30 in Stock
Relay Therapeutics (NASDAQ:RLAY) insider Peter Rahmer sold 1,354 shares of the company's stock for $11,441.30 on January 28th, reducing his holding to 276,610 shares. This sale follows another larger transaction on January 27th and contributes to a negative sentiment surround the stock, alongside sales by other insiders like CFO Thomas Catinazzo and Donald Bergstrom. Despite these insider sales, analysts currently maintain a "Moderate Buy" rating for RLAY with a consensus price target of $16.57.
Relay Therapeutics (RLAY) Valuation Check After Analyst Upgrades And Zovegalisib Breast Cancer Data
Relay Therapeutics (RLAY) is gaining investor attention due to recent analyst upgrades and interim data for its breast cancer drug zovegalisib. Despite a recent share price decline, the stock has shown significant one-year returns. Currently trading at US$7.71 with analyst targets between US$12 and US$14 and a P/B ratio of 2.2x, the article explores whether RLAY is undervalued given its clinical stage and ongoing losses.
Thomas Catinazzo Sells 13,820 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock
Relay Therapeutics CFO Thomas Catinazzo sold 13,820 shares of the company's stock on January 27th for $105,308.40, and an additional 1,695 shares on January 28th for $14,322.75, decreasing his holdings by 5.22%. Despite the insider selling, analysts have a "Moderate Buy" consensus rating and a target price of $16.57 for RLAY, which recently reported an EPS of ($0.43). The company's stock trades at $7.71 with a market capitalization of $1.34 billion.
Relay Therapeutics president sells $166k in RLAY stock By Investing.com
Donald A. Bergstrom, President of Research and Development at Relay Therapeutics, Inc. (NASDAQ:RLAY), sold 21,581 shares of company stock across two transactions on January 27 and 28, 2026, totaling approximately $166,676. These sales primarily covered income tax withholding obligations related to the vesting of restricted stock units. Despite these sales, analysts maintain a "Strong Buy" consensus for RLAY, noting the stock's significant six-month gain and the company's solid financial position with more cash than debt, though it is experiencing a quick cash burn.
Relay Therapeutics president sells $166k in RLAY stock
Donald A. Bergstrom, President of Research and Development at Relay Therapeutics, Inc. (RLAY), sold 21,581 shares of company stock across two days for a total of approximately $166,676. These sales were primarily for tax withholding obligations related to restricted stock units. Despite these transactions, analysts maintain a "Strong Buy" rating on RLAY, which has seen significant stock performance and has promising investigational drug results.
Oppenheimer Upgrade Fuels Relay Therapeutics Rally On Zovegalisib Optimism (NASDAQ:RLAY)
Oppenheimer has upgraded Relay Therapeutics (RLAY) to Outperform with a $14 price target, citing optimism for zovegalisib in PIK3CA-mutant HR+/HER2- metastatic breast cancer due to its differentiated safety and efficacy profile as a mutant-selective PI3Kα inhibitor. The company's strong cash position of $596M is expected to fund operations into 2029, supporting ongoing pivotal Phase 3 and expansion studies. Key upcoming catalysts include topline Phase 3 ReDiscover-2 data in mid-2026, which could provide a competitive advantage if rival treatments underperform.
Relay Therapeutics shares climb after Oppenheimer lifts rating
Oppenheimer has upgraded Relay Therapeutics stock, leading to a climb in its shares. Unfortunately, the full content of the article is unavailable, so specific details regarding the upgrade or the reasons behind it cannot be provided at this time.
Oppenheimer Upgrades Relay Therapeutics (RLAY) with Positive Out
Oppenheimer has upgraded Relay Therapeutics (RLAY) to an outperform rating with a $14 price target, citing the potential for its lead drug, zovegalisib, to capitalize on anticipated underperformance of a competitor's drug. Relay Therapeutics, a clinical-stage precision medicine company, shows strong liquidity and low debt but faces significant profitability challenges and insider selling. The company operates in the volatile biotechnology sector, and its valuation metrics reflect a speculative growth profile.
Relay Therapeutics (RLAY) Upgraded by Oppenheimer, Price Target Set at $14.00 | RLAY Stock News
Oppenheimer has upgraded Relay Therapeutics (RLAY) stock from "Perform" to "Outperform," setting a new price target of $14.00, reflecting increased confidence in the company's growth potential. This upgrade follows a series of fluctuating analyst ratings and price target adjustments for RLAY. Despite a high average analyst price target of $14.60 suggesting significant upside, GuruFocus's GF Value estimate suggests a potential downside from the current price.
Relay Therapeutics stock rises after Oppenheimer upgrade
Relay Therapeutics Inc. (NASDAQ:RLAY) stock increased 5.8% in premarket trading after Oppenheimer upgraded the biotech company from "Perform" to "Outperform" with a $14 price target. Analyst Matt Biegler cited the potential tailwinds for Relay's zovegalisib, a mutant-selective inhibitor, expecting a competitor's clinical trial to underperform. This upgrade reflects Oppenheimer's confidence in Relay's competitive position in targeted cancer therapies.
Relay Therapeutics stock rises after Oppenheimer upgrade
Relay Therapeutics Inc (NASDAQ:RLAY) stock increased by 5.8% in premarket trading after Oppenheimer upgraded the company from Perform to Outperform, setting a price target of $14.00. Analyst Matt Biegler cited potential advantages for Relay's zovegalisib over a competitor's treatment, gedatolisib, in an upcoming clinical trial. Oppenheimer believes that the competitive landscape will favor Relay's technology.
Oppenheimer upgrades Relay Therapeutics stock rating on gedatolisib concerns
Oppenheimer has upgraded Relay Therapeutics (NASDAQ:RLAY) from Perform to Outperform with a price target of $14.00, citing concerns about gedatolisib's upcoming VIKTORIA-1 readout which could benefit Relay’s competing drug. The firm anticipates gedatolisib's trial to underperform, setting a "beatable bar" for Relay's zovegalisib, which has shown promising interim results in breast cancer treatment. Relay's stock has seen significant gains despite recent volatility, with analysts revising earnings upward.
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Recommendation of "Moderate Buy" by Brokerages
Seven analysts have given Relay Therapeutics (NASDAQ:RLAY) an average recommendation of "Moderate Buy," with an average 12-month price target of $17.00. The company recently reported a quarterly EPS miss, and analysts project an EPS of approximately -$2.55 for the current fiscal year. Insiders have sold shares totaling about $1.46 million in the last three months, while institutional investors hold a significant majority of the stock.
Have Relay Therapeutics Insiders Been Selling Stock?
Relay Therapeutics (NASDAQ:RLAY) recently saw its CEO, President & Director, Sanjiv Patel, sell US$338k worth of stock. While this sale represented only a small portion of his holdings (3.0%), it follows another larger sale of US$818k earlier in the year at a lower price. The article highlights that while insider selling isn't a positive sign, the insider ownership of 2.2% (worth US$30m) indicates some alignment, though overall the insiders have been selling and not buying in the last year.
Insider Selling: Relay Therapeutics (NASDAQ:RLAY) CEO Sells $337,573.76 in Stock
Relay Therapeutics CEO Sanjiv Patel sold 43,168 shares of the company's stock for $337,573.76 on January 6th, reducing his stake by 6.13%. This follows another significant sale in November, indicating a trend of insider selling. Despite these sales and recent negative EPS, analysts maintain a "Moderate Buy" rating with an average price target of $17.00 for RLAY.
Relay Therapeutics announces analysis of data for zovegalisib
Relay Therapeutics has announced data analysis for zovegalisib. The information was released publicly five days prior to the article's crawl time.
Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week
This article from MSN explains why Relay Therapeutics stock experienced a significant ~15% increase during the week. The full content of the article is not available in the provided input, so the specific reasons for the stock surge remain unknown.
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Relay Therapeutics, Inc. (NASDAQ:RLAY) has received a consensus "Moderate Buy" rating from seven brokerages, with an average 12-month price target of $17.00. Institutional investors own 96.98% of the company, with notable increases in positions by firms like Commodore Capital LP. Despite recent insider selling totaling $1.12 million, the company's stock shows a 50-day moving average price of $7.39 and a two-hundred day moving average price of $5.20.
Relay Therapeutics (NASDAQ:RLAY) Shares Up 4.9% - Here's What Happened
Relay Therapeutics (NASDAQ:RLAY) saw its shares rise by 4.9% on Wednesday, closing at $8.72 on unusually light trading volume. Despite negative EPS and recent insider selling, analysts generally hold a "Moderate Buy" consensus with an average target price of $17. The clinical-stage biotech company specializes in precision oncology therapies using an integrated scientific platform.
Congress Asset Management Co. Has $2.13 Million Stock Holdings in Relay Therapeutics, Inc. $RLAY
Congress Asset Management Co. significantly increased its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) in the third quarter, now holding 408,842 shares valued at approximately $2.13 million. The company has an average analyst rating of "Moderate Buy" with a consensus price target of $17.00. Despite institutional buying, some insiders have sold shares, and the company is reporting negative EPS.
Relay Therapeutics signals slowdown to recharge after busy year
Relay Therapeutics, after a busy 2025 marked by significant scientific progress like the efficacy subset analysis for zovegalisib at SABCS25, is now signaling a slowdown. The company encourages its team to take time to recharge and celebrate with family and friends, emphasizing employee well-being and the importance of rest and reflection after a period of hard work. This focus on balance complements their innovation in areas such as breast cancer research.
